October 13th, 2014
This week’s topics include a comparison of once-weekly dulaglutide and once-daily liraglutide in metformin-treated patients with type 2 diabetes and variation in patients’ perceptions of elective PCI in stable CAD.
September 18th, 2014
The FDA said today that it had approved dulaglutide, Lilly’s once-weekly injection to control blood sugar in adults with type 2 diabetes. The drug will be marketed under the brand name of Trulicity. The FDA said that the safety and efficacy of dulaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, had been studied in 3,342 type 2 diabetics. The drug […]